Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlook

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR1.91), EUR0.55 worse than the analyst estimate of (EUR1.36). Revenue for the quarter came in at EUR36 million versus the consensus estimate of EUR83.7 million.

The company sees Skytrofa revenue EU220 million to EU240 million, down from the prior range of EU320 million to EU340 million, vs. estimated EU350.7 million

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Rocket Lab joins U.S. Space Force's $981M NITE-STAR contract